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Several studies reported sex differences in aldosterone. It is unknown
whether these differences are associated with differences in volume
regulation. Therefore we studied both aldosterone and extracellular
volume in men and women on different sodium intakes. In healthy
normotensive men (n  18) and premenopausal women (n  18) we
investigated plasma aldosterone, blood pressure, and extracellular
volume (125I-iothalamate), during both low (target intake 50 mmol
Na/day) and high sodium intake (target intake 200 mmol Na/day)
in a crossover setup. Furthermore, we studied the adrenal response to
angiotensin II infusion (0.3, 1.0, and 3.0 ng·kg1·min1 for 1 h) on
both sodium intakes. Men had a significantly higher plasma aldoste-
rone, extracellular volume, and systolic blood pressure than women
during high sodium intake (P  0.05). During low sodium intake,
extracellular volume and blood pressure were higher in men as well
(P  0.05), whereas the difference in plasma aldosterone was no
longer significant (P  0.252). The adrenal response to exogenous
angiotensin II was significantly lower in men than in women on both
sodium intakes. Constitutive sex differences in the regulation of
aldosterone, characterized by a higher aldosterone and a lower adrenal
response to exogenous angiotensin II infusion in men, are associated
with a higher extracellular volume and blood pressure in men. These
findings suggest that sex differences in the regulation of aldosterone
contribute to differences in volume regulation between men and
women.
extracellular volume; renin-angiotensin system; sex; aldosterone;
healthy volunteers
THE RENIN-ANGIOTENSIN-ALDOSTERONE system (RAAS) is a main
regulatory system of volume homeostasis and blood pressure.
Aldosterone secretion induces sodium and water retention in
the distal tubules of the kidneys and is stimulated by angio-
tensin II (ANG II) and a high plasma potassium concentration.
Differences in the RAAS between men and women have
been described (8, 10, 14, 17, 18). Higher aldosterone levels
have been reported in men, both in normotensive and in
hypertensive subjects (9, 17). However, it is unknown whether
sex differences in aldosterone levels are associated with func-
tional consequences on volume homeostasis (14). As the major
effect of aldosterone is sodium and water retention, we hypoth-
esize that a higher aldosterone level in men is associated with
a higher extracellular volume (ECV). Furthermore, sex differ-
ences in regulation of aldosterone production are not well
studied.
To study sex differences in RAAS and ECV, maintaining
standardized study conditions is mandatory. RAAS hormone
levels vary with sodium diet and, in women, with phase of the
menstrual cycle (24). Therefore, in this study we investigated
sex differences in aldosterone levels, ECV, and blood pressure
during low and high sodium intake, in a steady state and
standardized for menstrual cycle. Furthermore, we studied sex
differences in the adrenal response to ANG II infusion in these
standardized conditions, during both sodium intakes.
METHODS
Study population. The study population consisted of 36 healthy,
Caucasian subjects (women, n  18; men, n  18) who took part in
the Groningen Renal Hemodynamic Cohorts (GRECO) program,
which is an ongoing study program on renal hemodynamic studies in
different populations (healthy and chronic kidney disease patients)
with standardized measurements and harmonized protocols for differ-
ent subsequent studies, allowing combined analyses of the different
substudies. The women were studied in the Response to Angiotensin
II in Formerly Preeclamptic Women (RETAP) substudy and com-
pared with men from the Gene-Environment substudy (15, 29). All
subjects were nonsmokers and normotensive, having a sitting systolic
blood pressure140 mmHg and diastolic blood pressure90 mmHg
measured by Dinamap, and were not treated with an antihypertensive
drug. Their medical histories revealed no significant diseases. Sub-
jects with obesity [body mass index (BMI) 30 kg/m2 at screening]
were excluded. Physical examination and electrocardiography did not
reveal any abnormalities. None of the women were users of oral
contraceptive medication or were pregnant. Both studies were ap-
proved by the local medical ethical committee (METc no.: RETAP
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study 2010/294, http://www.trialregister.nl/trialreg/index.asp; trial
registration no. 2635, Gene-Environment study 2001/012), and all
subjects gave written informed consent in accordance with the Dec-
laration of Helsinki.
Study protocol. In both women and men, a standardized crossover
protocol was performed as described earlier (26, 29), which consisted
of two 1-wk periods: in random order a 7-day period on a low-sodium
diet (LS; aim: 50 mmol Na/day) and a 7-day period on a high-
sodium diet (HS; aim: 200 mmol Na/day), with stable potassium
intake. This was achieved by dietary counseling. For assessment of
dietary compliance and the achievement of a stable sodium balance,
24-h urine was collected on days 3 and 6 during each period. In men
the study periods were done consecutively, and in women these
periods were divided by one menstrual cycle, to avoid the influence of
momentary sex hormones on aldosterone levels and ANG II respon-
siveness (14, 19). On day 7 of both study periods, during which all
women were in the midfollicular phase (day 7 2 of menstrual
cycle), the subjects reported to the research unit at 8 AM after an
overnight fast. Body weight, length, and waist-to-hip ratio were
measured at the start of this day. An intravenous cannula was inserted
into each forearm, one for drawing blood samples and the other for
infusion of ANG II. Subjects received standardized meals and
fluids during the day, with sodium intake adjusted to the prescribed
diet. To ensure sufficient urine output, infusion of 250 ml/h of 5%
glucose was administered, and every hour, 250 ml of oral fluids
were provided. Baseline values for blood pressure were obtained
from 10 AM to 12 AM. Between 12 AM and 3 PM, ANG II
(Clinalfa; Merck Biosciences, Läufelfingen, Switzerland) was ad-
ministered intravenously, at a constant rate in doses of 0.3, 1, and
3 ng·kg1·min1 each during 1 h.
Blood pressure and heart rate were measured with an automated
sphygmomanometer (Dinamap; GE Medical Systems, Milwaukee,
WI) at 15-min intervals. Subjects were seated in a quiet room in a
semisupine position, with their arm in resting position. During ANG
II infusions, blood pressure was measured at 5-min intervals. Appro-
priate blood pressure cuff was determined on the basis of arm
circumference.
ECV was measured as the distribution volume of 125I-iothalamate
during steady state, as described in more detail previously (30). This
was performed before ANG II infusions. Briefly, the distribution
volume of 125I-iothalamate is calculated from the plasma level of
125I-iothalamate divided by the total amount of 125I-iothalamate in the
body, which equals the amount infused minus the amount excreted. It
is calculated as Sum(I V) Bolus Sum(U  V)/P (where I V
is the infusion rate of 125I-iothalamate, U V is the urinary excretion
of 125I-iothalamate, and P represents 125I-iothalamate values in
plasma at the end of each clearance period) and expressed as ECV/
body surface area (BSA), i.e., liters per 1.73 m2 BSA. BSA was
calculated according to the DuBois-DuBois formula (7).
Sample collection and analytical methods. Blood samples were
drawn at baseline and after each hour of ANG II infusion. Blood for
measuring plasma aldosterone and renin was collected in precooled
tubes and immediately centrifuged at 4°C for 10 min (3,000 rpm).
Plasma was subsequently stored at 80°C until analysis. Aldosterone
was measured with a commercially available radioimmunoassay kit
(Diagnostic Products, Los Angeles, CA). Active plasma renin con-
centration (APRC) was measured with a radioimmunoassay that
detects the amount of ANG I produced per hour in the presence of
excess exogenous angiotensinogen as described previously (6) (nano-
grams of ANG I produced per liter of plasma per hour; CisBio
International, Codolet, France). Longitudinal quality controls were
run in all assays to validate the results over time. The levels of urinary
sodium, potassium, and urea were determined from the 24-h urine
collections of the subjects and assessed using an automated clinical
chemistry analyzer (Roche Modular; Basel, Switzerland).
Statistical analysis. Statistical analysis was performed using SPSS
for Windows (version 22.0). Data were tested for normality using
histograms and the Kolmogorov-Smirnov test for normal distribution.
Parametric data are presented as means SD and analyzed using
Student’s t-test or paired t-test. Nonparametric data are presented as
medians (25th to 75th percentiles) and analyzed using the Mann-
Whitney U-test or Wilcoxon signed-rank test. Sex differences in ECV
and aldosterone during a low-sodium diet and high-sodium diet were
analyzed by generalized estimating equations (GEE) analysis. Sex
differences in aldosterone response were determined using GEE
analysis. Statistical significance was accepted at P  0.05. The
association between plasma aldosterone and ECV was tested using
linear univariate regression analysis. To this end, plasma aldosterone
was log transformed to achieve normal distribution.
RESULTS
Baseline characteristics and urinary and blood parameters.
The baseline characteristics of the two groups are presented in
Table 1. There were no significant differences in age, waist-
to-hip ratio, and BMI. Height and BSA were, as expected,
significantly higher in men. Urinary albumin excretion was
normal in all subjects and did not differ between men and
women (data not shown). Blood and urinary parameters during
the different sodium intakes are shown in Table 2. Systolic
Table 1. Characteristics of subjects
Characteristic Women (n  18) Men (n  18) P
Age, yr 36  5 31  11 0.092
Waist-to-hip ratio 0.83 0.04 0.85  0.08 0.397
Height, cm 171 5 184  6 0.001*
BMI, kg/m2 23.2  2.7 23.2  2.2 0.969
BSA, m2 1.79  0.12 2.01  0.12 0.001*
Values are means SD. Differences between men and women are analyzed
using Student’s t-test. BMI, body mass index; BSA, body surface area.
*Statistically significant (P  0.05).
Table 2. Clinical parameters during low and high sodium
intake
Parameter
Women
(n  18)
Men
(n  18) P
SBP HS, mmHg 115  8 124  12 0.011*
SBP LS, mmHg 110  9† 122  10 0.001*
DBP HS, mmHg 71  8 73  8 0.474
DBP LS, mmHg 67  7† 72  7 0.039*
Heart rate HS, beats/min 67  8 57  7 0.001*
Heart rate LS, beats/min 67  8 60  11 0.021*
Plasma potassium HS, mmol/l 3.9  0.2 3.9  0.3 0.667
Plasma potassium LS, mmol/l 4.0  0.2 4.0  0.2 0.944
Urinary sodium HS, mmol/24 h 221  64 200  70 0.356
Urinary sodium LS, mmol/24 h 39  14† 41  27† 0.764
Urinary potassium HS, mmol/24 h 80  34 68  22 0.215
Urinary potassium LS, mmol/24 h 66  21 76  30 0.267
Urinary creatinine HS, mmol/24 h 9.8  1.5 15.3  2.3 0.001*
Urinary creatinine LS, mmol/24 h 9.8  1.9 13.9  2.9 0.001*
Aldosterone HS, ng/l 26 (10–34) 37 (24–63) 0.014*
Aldosterone LS, ng/l 92 (72–145)† 121 (77–154)† 0.252
APRC HS, ng ANG I·ml1·h1 4.0 (2.5–6.0) 2.8 (1.2–3.5) 0.024*
APRC LS, ng ANG I·ml1·h1 9.5 (8.1–12.7)† 5.6 (4.3–7.4)† 0.001*
Values are means SD or medians with 25th to 75th percentiles in
parentheses. Differences between men and women are analyzed using Stu-
dent’s t-test or Mann-Whitney U-test. Differences between low and high
sodium intake are tested using a paired t-test or Wilcoxon signed-rank test. HS,
high sodium intake; LS, low sodium intake; SBP, systolic blood pressure;
DBP, diastolic blood pressure; APRC, active plasma renin concentration.
*Statistically significant (P  0.05). †P  0.05 LS vs. HS.
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blood pressure was higher in men during both sodium intakes
(LS: 122  10 vs. 110  9 mmHg, P  0.001; HS: 124  12
vs. 115  8 mmHg, P  0.011). Diastolic blood pressure was
higher in men during a low-sodium diet (72  7 vs. 67  7,
P 0.039) but not significantly different during a high-sodium
diet (73  8 vs. 71  8 mmHg, P  0.474). Urinary sodium
excretion and urinary potassium excretion were equal between
both groups, which reflects comparable sodium and potassium
intakes during the respective dietary weeks.
RAAS hormones, extracellular volume, and their association.
Aldosterone was significantly higher in men than in women
during a high-sodium diet [37 (24–63) vs. 26 (10–34) ng/l,
P  0.014]. During a low-sodium diet, this difference was no
longer statistically significant [92 (72–145) vs. 121 (77–154)
ng/l, P  0.252; Table 2 and Fig. 1A]. APRC was significantly
higher in women during both sodium intakes [LS: 9.5 (8.1–
12.7) vs. 5.6 (4.3–7.4) ng ANG I·ml1·h1, P 0.001; HS: 4.0
(2.5–6.0) vs. 2.8 (1.2–3.5) ng ANG I·ml1·h1, P  0.024;
Table 2]. ECV data (scaled as ECV/1.73 m2 BSA) are shown
in Fig. 1B. Men had a significantly higher ECV than women
during both sodium intakes (LS: 13.3  1.8 vs. 16.3  2.6
liters/1.73 m2, P  0.001; HS: 14.4  2.2 vs. 17.4  2.9
liters/1.73 m2, P  0.002). As expected, ECV was higher
during high sodium intake than during low sodium intake in
both men (P  0.023) and women (P  0.006). Similar results
were seen when scaling ECV to lean body mass or to weight
(data not shown).
In the whole population, higher plasma aldosterone was
associated with higher ECV during a high-sodium diet
(B  1.758, P  0.024; see Fig. 2). During low sodium intake,
this trend was borderline significant (B  1.526, P  0.103).
When investigating this association per sex, no statistically
significant correlations were found (data not shown). The
extent of ECV reduction after sodium restriction was not
correlated with the rise in aldosterone or with blood pressure
decline. Additionally, blood pressure reduction after sodium
restriction was not statistically significantly correlated with the
rise in aldosterone.
Adrenal response to ANG II infusion. To study sex differ-
ences in the regulation of aldosterone, we performed ANG II
infusions during low- and high-sodium diets. In both men and
women the increasing doses of ANG II led to a progressive
increase in aldosterone levels (Fig. 3). In women this increase
in aldosterone levels was more pronounced than in men during
both sodium intakes (analysis of dose-response curves by GEE
analyses).
DISCUSSION
This is the first study providing a systematic comparison of
aldosterone and volume status in healthy young adult men and
women, under strictly standardized conditions on both high-
and low-sodium diets. Our data suggest that constitutive sex
differences in aldosterone levels may lead to altered volume
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Fig. 1. Plasma aldosterone and extracellular vol-
ume in men and women during high and low
sodium intake. Median (75th percentile) plasma
aldosterone (A) and ECV (B) during high sodium
and low sodium intake in women (white box plots)
and men (gray box plots) The whiskers represent
the 10th and 90th percentiles. BSA, body surface
area. The response of extracellular volume and
aldosterone after the change in sodium intake was
not significantly different between both groups
(GEE analysis). *Significantly different from
women (GEE analysis), P  0.05. #Significantly
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Fig. 2. Scatterplot of distribution of extracel-
lular volume (ECV) against plasma aldoste-
rone during high- and low-sodium diets. A:
high-sodium diet. B: low-sodium diet. In the
whole population a higher plasma aldosterone
was statistically significant associated with a
higher ECV during high sodium intake and
borderline significant during low sodium in-
take.
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status with a higher ECV and blood pressure in men. Addi-
tionally, men have a reduced adrenal response to exogenous
ANG II infusion, compatible with a higher effect of endoge-
nous ANG II on adrenal aldosterone secretion (25). Therefore
the difference in aldosterone levels might be ANG II mediated.
We found a higher plasma aldosterone in men than in
women. This is in accordance with earlier studies, in both
healthy and hypertensive subjects (9, 17). During a low-sodium
diet, the difference in aldosterone between men and women did
not quite reach statistical significance.
The higher aldosterone in men that we report could be
explained by different mechanisms. First, differences in plasma
potassium concentrations could influence aldosterone levels;
however, these were similar in men and women. Second,
higher levels of plasma ACTH levels could stimulate addi-
tional aldosterone secretion in men; however, these were not
measured in the current study. Last, higher circulating levels of
endogenous ANG II or higher adrenal sensitivity to endoge-
nous ANG II could contribute to the higher aldosterone levels
in men. However, endogenous ANG II was not measured as
this is notoriously difficult to interpret, and therefore we prefer
assessing endogenous ANG II using infusion of exogenous
ANG II. Indeed, we found that the adrenal responses to
exogenous ANG II infusion were less pronounced in men, on
both sodium intakes. A lower adrenal response to exogenous
ANG II could be due to several factors related to greater
endogenous ANG II activity, such as an increased tissue
concentration of endogenous ANG II or increased density of
the ANG II receptor (25). Therefore the reduced adrenal
response to ANG II infusion that we found in men suggests that
endogenous ANG II facilitates the higher aldosterone levels in
men. We previously reported on sex differences in ANG II
response—with respect to blood pressure, inversely to the
present manuscript—with a larger response in men during high
sodium (27). This is in line with the reciprocal response to
altered endogenous ANG II status between ANG II sensitivity
of the vascular bed and that of the adrenal gland (25).
Furthermore, we are the first to demonstrate sex differences
in volume status under well-controlled conditions. We found
that ECV was higher in men, during both a high- and a
low-sodium diet. This finding was consistent when normaliz-
ing ECV to other body dimensions (i.e., length and lean body
mass), marking the robustness of our data. This is in line with
the results of Peters et al., who found a higher ECV (scaled to
BSA) in men, in a large cohort study of healthy prospective
kidney donors (20). However, in their study, sodium status was
not standardized, and the ECV difference did not persist when
scaled to other body dimensions or when corrected for potas-
sium intake. Our data demonstrate an effect of sodium intake
on ECV, with a rise in ECV during a high-sodium diet. This
shows that it is relevant to account for sodium intake when
interpreting ECV.
We found a higher systolic blood pressure in men, under
well-controlled conditions. Heart rate was higher in women
than in men, which is in line with known literature on healthy
young adults (28). In the hypertensive population, it has been
well established that blood pressure is higher in men than in
premenopausal women (21, 23). Here, we show that in nor-
motensive subjects this is true as well, which is in line with
previous studies (12, 31). This might be mediated through
gonadal hormones; testosterone levels in men might increase
systolic blood pressure (SBP; 13), whereas estrogen levels in
women might protect against high SBP (21). It has also been
suggested that sex differences in sympathetic regulation of the
cardiovascular system lead to differences in SBP (2). Alterna-
tively, as we found that men have higher aldosterone levels and
higher ECV, excess volume and sodium retention elicited
through aldosterone might lead to higher SBP. Indeed, we
found an association between higher aldosterone and higher
ECV. However, this association was not found in women and
men separately and was only borderline significant during a
low-sodium diet. Although our data support the hypothesis that
aldosterone causes a higher SBP in men through volume
retention, intervention with an aldosterone antagonist such as
spironolactone or eplerenone would provide further evidence.
We found that SBP decline after sodium restriction was
subtle and, in men, did not reach statistical significance. This
demonstrates an intact blood pressure homeostasis in non-
sodium-sensitive normotensive young adults. The absence of a
visible correlation between ECV decline and SBP decline after
sodium restriction further illustrates the intact feedback loop to
maintain blood pressure despite volume loss.
Our study has limitations. First, our study shows an associ-
ation between sex differences in aldosterone and ECV but
cannot provide proof of the causality of this association.
Second, we studied premenopausal women in the midfollicular
phase; caution is warranted when extrapolating our findings.
Aldosterone levels and ECV are influenced by phase of the
menstrual cycle and, importantly, by menopause (3, 4). It has
been shown that after menopause the sex differences in aldo-
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sterone levels and in blood pressure disappear (5, 16, 22, 32).
Furthermore, we found significantly lower APRC in men than
in women, irrespective of sodium intake. This is in contrast to
earlier studies, which describe a lower plasma renin in pre-
menopausal women than in men (1, 11). This could not be
explained through phase of the menstrual cycle, as renin levels
were found to be lower during the follicular phase than during
the luteal phase (1). As we measured APRC in two different
substudies of the GRECO cohort and the measurements were
performed several years apart, these results should be inter-
preted with caution.
In conclusion, men have a higher aldosterone, ECV, and
SBP than women. Furthermore, the adrenal response to ANG
II infusion is less pronounced in men, suggesting a higher
contribution of endogenous ANG II to adrenal aldosterone
secretion. Taken together, this well-controlled physiological
study gives in-depth data on possible mechanisms in which sex
difference in aldosterone could lead to higher ECV and blood
pressure in men.
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